GLG Partners’s VanEck Biotech ETF BBH Stock Holding History

GLG Partners’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-10,909	Closed	-$1.38M	–	417
2015 Q4	$1.38M	Sell	10,909 -10,620	-49%	-$1.3M	0.04%	279
2015 Q3	$2.46M	Hold	21,529	–	–	0.07%	265
2015 Q2	$2.9M	Hold	21,529	–	–	0.08%	258
2015 Q1	$2.79M	Hold	21,529	–	–	0.09%	213
2014 Q4	$2.48M	Hold	21,529	–	–	0.07%	225
2014 Q3	$2.28M	Buy	21,529 +2,163	+11%	+$219K	0.05%	290
2014 Q2	$1.85M	Buy	19,366 +9,262	+92%	+$830K	0.04%	261
2014 Q1	$919K	Buy	+10,104	New	+$982K	0.02%	306

Other funds holding BBH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

LFM

Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

GLG Partners's BBH Position: Q1 2016 in Review

GLG Partners sold out of VanEck Biotech ETF (BBH) in Q1 2016, closing a stake of 10,909 shares — an estimated $1.38M sold.

GLG Partners first reported a position in BBH in Q1 2014 and held it in 8 quarters. The position peaked at $2.9M in Q2 2015. 71 funds tracked by Wall St. Rank hold BBH as of Q1 2016.

GLG Partners reported no remaining VanEck Biotech ETF position as of Q1 2016 after selling out during the quarter.
GLG Partners sold 10,909 VanEck Biotech ETF shares in Q1 2016, an estimated $1.38M.
GLG Partners first reported a position in VanEck Biotech ETF in Q1 2014 and held it in 8 quarters.
GLG Partners's VanEck Biotech ETF position peaked at $2.9M in Q2 2015.
71 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2016.

Based on GLG Partners's 13F filing for Q1 2016, filed 16 May 2016.